| 1 | Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. (Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT) J Clin Oncol 2020 Nov 20;38(33):3895-3904 74 Citations |
| 1 | A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. (Oza AM, Estevez-Diz M, Grischke EM, Hall M, Marmé F, Provencher D, Uyar D, Weberpals JI, Wenham RM, Laing N, Tracy M, Freshwater T, Lee MA, Liu J, Qiu J, Rose S, Rubin EH, Moore K) Clin Cancer Res 2020 Sep 15;26(18):4767-4776 52 Citations |
| 1 | Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. (Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, D'Amelio AM Jr, Ellis C, Ibrahim N, Yan L) Cancer Chemother Pharmacol 2020 Apr;85(4):673-683 32 Citations |
| 1 | A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. (Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS) Clin Cancer Res 2019 Sep 15;25(18):5475-5484 13 Citations |
| 1 | Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature. (Gerrard DL, Wang Y, Gaddis M, Zhou Y, Wang J, Witt H, Lin S, Farnham PJ, Jin VX, Frietze SE) J Cell Biochem 2019 Mar;120(3):3056-3070 6 Citations |
| 1 | Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. (Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA) Clin Cancer Res 2017 Aug 01;23(15):4027-4034 31 Citations |
| 1 | Inhibitory effects of merocyanine 540-mediated photodynamic therapy on cellular immune functions: A role in the prophylaxis of graft-versus-host disease? (Traul DL, Sieber F) J Photochem Photobiol B 2015 Dec;153:153-63 12 Citations |
| 1 | Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. (Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S) J Clin Oncol 2015 Dec 01;33(34):4023-31 372 Citations |
| 1 | AMG2850, a potent and selective TRPM8 antagonist, is not effective in rat models of inflammatory mechanical hypersensitivity and neuropathic tactile allodynia. (Lehto SG, Weyer AD, Zhang M, Youngblood BD, Wang J, Wang W, Kerstein PC, Davis C, Wild KD, Stucky CL, Gavva NR) Naunyn Schmiedebergs Arch Pharmacol 2015 Apr;388(4):465-76 19 Citations |
| 1 | Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. (Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA 3rd, Messersmith WA) Lancet Oncol 2012 Aug;13(8):773-81 420 Citations |
| 1 | Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. (Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA) Lancet Oncol 2012 Aug;13(8):782-9 429 Citations |
| 1 | Photochemically generated elemental selenium forms conjugates with serum proteins that are preferentially cytotoxic to leukemia and selected solid tumor cells. (Daziano JP, Günther WH, Krieg M, Tsujino I, Miyagi K, Anderson GS, Sampson RW, Ostrowski MD, Muir SA, Bula RJ, Sieber F) Photochem Photobiol 2012;88(2):448-60 9 Citations |
| 1 | A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. (Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik JM, Hylander-Gans L, Osmukhina A, Huszar D, Herbst RS) Cancer Chemother Pharmacol 2012 Jan;69(1):165-72 30 Citations |
| 1 | Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. (Busse KH, Hadigan C, Chairez C, Alfaro RM, Formentini E, Kovacs JA, Penzak SR) J Acquir Immune Defic Syndr 2009 Oct 01;52(2):235-9 20 Citations |
| 1 | Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136). (Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ, Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D, EPIC (CCR100136) study team) HIV Med 2009 Feb;10(2):116-24 14 Citations |
| 1 | Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir. (Ramanathan R, Pau AK, Busse KH, Zemskova M, Nieman L, Kwan R, Hammer JH, Mican JM, Maldarelli F) Clin Infect Dis 2008 Dec 15;47(12):e97-9 37 Citations |
| 1 | Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals. (Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR) J Acquir Immune Defic Syndr 2008 Aug 15;48(5):561-6 18 Citations |
| 1 | Potentiation of the antitumor effect of Merocyanine 540-mediated photodynamic therapy by amifostine and amphotericin B. (Tsujino I, Miyagi K, Sampson RW, Sieber F) Photochem Photobiol 2006;82(2):458-65 19 Citations |
| 1 | Crystal violet combined with Merocyanine 540 for the ex vivo purging of hematopoietic stem cell grafts. (Miyagi K, Sampson RW, Sieber-Blum M, Sieber F) J Photochem Photobiol B 2003 Jul;70(3):133-44 13 Citations |
| 1 | Determining the relative efficacy of highly active antiretroviral therapy. (Louie M, Hogan C, Di Mascio M, Hurley A, Simon V, Rooney J, Ruiz N, Brun S, Sun E, Perelson AS, Ho DD, Markowitz M) J Infect Dis 2003 Mar 15;187(6):896-900 82 Citations |
| 1 | Preferential inactivation of paediatric solid tumour cells by sequential exposure to Merocyanine 540-mediated photodynamic therapy and Edelfosine: implications for the ex vivo purging of autologous haematopoietic stem cell grafts. (Anderson GS, Tsujino I, Miyagi K, Sampson R, Sieber F) J Photochem Photobiol B 2003 Feb;69(2):87-95 24 Citations |
| 1 | Anti-tumor effect of Merocyanine 540-mediated photochemotherapy combined with Edelfosine: potential implications for the ex vivo purging of hematopoietic stem cell grafts from breast cancer patients. (Anderson GS, Miyagi K, Sampson RW, Sieber F) J Photochem Photobiol B 2002 Nov;68(2-3):101-8 24 Citations |
| 1 | Postirradiation hyperthermia selectively potentiates the merocyanine 540-sensitized photoinactivation of small cell lung cancer cells. (Tsujino I, Anderson GS, Sieber F) Photochem Photobiol 2001 Feb;73(2):191-8 20 Citations |
| 1 | Tissue factor activity is increased in human endothelial cells cultured under elevated static pressure. (Silverman MD, Waters CR, Hayman GT, Wigboldus J, Samet MM, Lelkes PI) Am J Physiol 1999 Aug;277(2):C233-42 18 Citations |
| 1 | Role of cytoprotective mechanisms in the photochemical purging of autologous bone marrow grafts. (Yamazaki T, Sato Y, Sieber F) Exp Hematol 1997 Jul;25(7):629-37 21 Citations |
| 1 | Photochemical purging of autologous bone marrow grafts: assessment of damage to stem cells and the microenvironment in long-term marrow cultures. (Kubo Y, Sieber F) Bone Marrow Transplant 1997 Jul;20(1):27-31 9 Citations |
| 1 | Effect of hypothermia on the merocyanine 540-mediated purging of hematopoietic cells. (Yamazaki T, Sieber F) J Hematother 1997 Feb;6(1):31-9 10 Citations |
| 1 | The alkyl-lysophospholipid, ET-18-OCH3 synergistically enhances the Merocyanine 540-mediated photoinactivation of leukemia cells: implications for the extracorporeal purging of autologous hematopoietic stem cells. (Yamazaki T, Sieber F) Bone Marrow Transplant 1997 Jan;19(2):113-9 22 Citations |
| 1 | Inactivation of photosensitizing merocyanine dyes by plasma, serum and serum components. (Anderson GS, Günther WH, Searle R, Bilitz JM, Krieg M, Sieber F) Photochem Photobiol 1996 Oct;64(4):683-7 18 Citations |
| 1 | Potentiation of merocyanine 540-mediated photodynamic therapy by salicylate and related drugs. (Traul DL, Anderson GS, Bilitz JM, Krieg M, Sieber F) Photochem Photobiol 1995 Oct;62(4):790-9 6 Citations |
| 2 | Enhancement of merocyanine 540 uptake and photodynamic cell killing by salicylates. (Feix JB, Anderson MS, Kalyanaraman B) Cancer Res 1994 Jul 01;54(13):3474-8 4 Citations |
| 1 | Importance of cellular defense mechanisms in the photodynamic purging of autologous bone marrow grafts. (Sieber F, Gaffney DK, Yamazaki T, Qiu K) Prog Clin Biol Res 1994;389:147-54 2 Citations |
| 1 | Merocyanine 540-sensitized photoinactivation of high-grade non-Hodgkin's lymphoma cells: potential application in autologous BMT. (Itoh T, Messner HA, Jamal N, Tweeddale M, Sieber F) Bone Marrow Transplant 1993 Sep;12(3):191-6 26 Citations |
| 2 | Enhancement of merocyanine 540-mediated phototherapy by salicylate. (Anderson MS, Kalyanaraman B, Feix JB) Cancer Res 1993 Feb 15;53(4):806-9 10 Citations |
| 1 | Phototherapy, photochemotherapy, and bone marrow transplantation. (Sieber F) J Hematother 1993;2(1):43-62 21 Citations |
| 1 | Photodamaging effects of merocyanine 540 on neutrophils and HL-60 cells. (Smith OM, Traul DL, Sieber F) Exp Hematol 1992 Dec;20(11):1278-84 18 Citations |
| 1 | The role of serum and serum components in the merocyanine 540-sensitized photoinactivation of K562 leukemia cells. (Gaffney DK, Sieber F) Biochim Biophys Acta 1992 Oct 27;1117(3):321-5 18 Citations |
| 1 | Merocyanine 540-sensitized photoinactivation of leukemia cells: effects of dose fractionation. (Qiu K, Sieber F) Photochem Photobiol 1992 Oct;56(4):489-93 12 Citations |
| 1 | Limited cell-cycle dependence of the merocyanine 540-sensitized photoinactivation of L1210 leukemia cells. (Qiu K, Traul DL, Sieber F) Photochem Photobiol 1992 Aug;56(2):277-80 2 Citations |
| 1 | Merocyanine 540-sensitized photoinactivation of human erythrocytes parasitized by Plasmodium falciparum. (Smith OM, Dolan SA, Dvorak JA, Wellems TE, Sieber F) Blood 1992 Jul 01;80(1):21-4 19 Citations |
| 1 | Merocyanine 540-sensitized photoinactivation of enveloped viruses in blood products: site and mechanism of phototoxicity. (O'Brien JM, Gaffney DK, Wang TP, Sieber F) Blood 1992 Jul 01;80(1):277-85 58 Citations |
| 1 | Antiviral effects of photosensitizing merocyanine dyes: implications for transfusion and bone marrow transplantation. (Sieber F, O'Brien JM, Gaffney DK) Semin Hematol 1992 Apr;29(2):79-87 9 Citations |
| 2 | Photobleaching of merocyanine 540: involvement of singlet molecular oxygen. (Singh RJ, Feix JB, Kalyanaraman B) Photochem Photobiol 1992 Apr;55(4):483-9 22 Citations |
| 1 | Structure-activity relationships in the antiviral and antileukemic photoproperties of merocyanine dyes. (Günther WH, Searle R, Sieber F) Semin Hematol 1992 Apr;29(2):88-94 25 Citations |
| 3 | Interactions of merocyanine 540 with human brain tumor cells. (Whelan HT, Traul DL, Przybylski C, Segura A, Thomas J, Meyer G, Sieber F) Pediatr Neurol 1992;8(2):117-20 6 Citations |
| 1 | Merocyanine-sensitized photoinactivation of enveloped viruses. (Sieber F, O'Brien JM, Gaffney DK) Blood Cells 1992;18(1):117-27; discussion 128 41 Citations |
| 2 | Production of singlet oxygen-derived hydroxyl radical adducts during merocyanine-540-mediated photosensitization: analysis by ESR-spin trapping and HPLC with electrochemical detection. (Feix JB, Kalyanaraman B) Arch Biochem Biophys 1991 Nov 15;291(1):43-51 65 Citations |
| 3 | Action spectra of the antileukemic and antiviral activities of merocyanine 540. (O'Brien JM, Singh RJ, Feix JB, Kalyanaraman B, Sieber F) Photochem Photobiol 1991 Nov;54(5):851-4 19 Citations |
| 2 | Cholesterol content but not plasma membrane fluidity influences the susceptibility of L1210 leukemia cells to merocyanine 540-sensitized irradiation. (Gaffney DK, Feix JB, Schwarz HP, Struve MF, Sieber F) Photochem Photobiol 1991 Nov;54(5):717-23 26 Citations |
| 1 | Photodynamic action of merocyanine 540 on erythrocyte membranes: structural perturbation of lipid and protein constituents. (Feix JB, Bachowski GJ, Girotti AW) Biochim Biophys Acta 1991 Sep 02;1075(1):28-35 54 Citations |
| 1 | Plasma membrane properties regulating the sensitivity of leukemia, lymphoma, and solid tumor cells to merocyanine 540-sensitized photoirradiation. (Smith OM, Gaffney DK, Anderson MS, McOlash L, Schober SL, Sieber F) Exp Hematol 1991 Sep;19(8):785-8 19 Citations |
| 1 | The immunoregulatory effects of merocyanine 540 on in vitro human T- and B-lymphocyte functions. (Lum LG, Yamagami M, Giddings BR, Joshi I, Schober SL, Sensenbrenner LL, Sieber F) Blood 1991 Jun 15;77(12):2701-6 15 Citations |
| 1 | Evaluation of merocyanine 540-sensitized photoirradiation as a method for purging malarially infected red cells from blood. (Smith OM, Traul DL, McOlash L, Sieber F) J Infect Dis 1991 Jun;163(6):1312-7 14 Citations |
| 2 | Photodynamic action of merocyanine 540 in artificial bilayers and natural membranes: action spectra and quantum yields. (Singh RJ, Feix JB, Pintar TJ, Girotti AW, Kalyanaraman B) Photochem Photobiol 1991 Apr;53(4):493-500 37 Citations |
| 2 | An electron spin resonance study of merocyanine 540-mediated type I reactions in liposomes. (Feix JB, Kalyanaraman B) Photochem Photobiol 1991 Jan;53(1):39-45 18 Citations |
| 1 | Modulation by thiols of the merocyanine 540-sensitized photolysis of leukemia cells, red cells, and herpes simplex virus type 1. (Gaffney DK, O'Brien JM, Sieber F) Photochem Photobiol 1991 Jan;53(1):85-92 30 Citations |
| 1 | Merocyanine 540-sensitized photoinactivation of soluble and membrane-bound enzymes in L1210 leukemia cells. (Gaffney DK, Sieber F) Cancer Res 1990 Dec 15;50(24):7765-9 29 Citations |
| 2 | Evaluation of merocyanine 540-sensitized photoirradiation as a means to inactivate enveloped viruses in blood products. (O'Brien JM, Montgomery RR, Burns WH, Gaffney DK, Sieber F) J Lab Clin Med 1990 Oct;116(4):439-47 58 Citations |
| 1 | Merocyanine 540-sensitized photoinactivation of leukemia cells: role of oxygen and effects on plasma membrane integrity and mitochondrial respiration. (Gaffney DK, Schober SL, Sieber F) Exp Hematol 1990 Jan;18(1):23-6 47 Citations |
| 1 | Mutagenicity of merocyanine 540-mediated photosensitization. (O'Brien JM, Sieber F) Exp Hematol 1989 Feb;17(2):166-70 9 Citations |
| 1 | Inactivation of Friend erythroleukemia virus and Friend virus-transformed cells by merocyanine 540-mediated photosensitization. (Sieber F, Krueger GJ, O'Brien JM, Schober SL, Sensenbrenner LL, Sharkis SJ) Blood 1989 Jan;73(1):345-50 50 Citations |
| 2 | Direct observation of singlet oxygen production by merocyanine 540 associated with phosphatidylcholine liposomes. (Feix JB, Kalyanaraman B, Chignell CF, Hall RD) J Biol Chem 1988 Nov 25;263(33):17247-50 40 Citations |
| 1 | Merocyanine 540. (Sieber F) Photochem Photobiol 1987 Dec;46(6):1035-42 124 Citations |
| 1 | Antiviral activity of merocyanine 540. (Sieber F, O'Brien JM, Krueger GJ, Schober SL, Burns WH, Sharkis SJ, Sensenbrenner LL) Photochem Photobiol 1987 Nov;46(5):707-11 65 Citations |
| 1 | Elimination of residual tumor cells from autologous bone marrow grafts by dye-mediated photolysis: preclinical data. (Sieber F) Photochem Photobiol 1987 Jul;46(1):71-6 30 Citations |
| 4 | Photodynamic action of merocyanine 540 on artificial and natural cell membranes: involvement of singlet molecular oxygen. (Kalyanaraman B, Feix JB, Sieber F, Thomas JP, Girotti AW) Proc Natl Acad Sci U S A 1987 May;84(9):2999-3003 168 Citations |
| 1 | Dye-mediated photolysis of normal and neoplastic hematopoietic cells. (Sieber F, Stuart RK, Rowley SD, Sharkis SJ, Sensenbrenner LL) Leuk Res 1987;11(1):43-9 59 Citations |
| 1 | Dye-mediated photolysis of human neuroblastoma cells: implications for autologous bone marrow transplantation. (Sieber F, Rao S, Rowley SD, Sieber-Blum M) Blood 1986 Jul;68(1):32-6 65 Citations |
| 1 | Dye-mediated photosensitization of murine neuroblastoma cells. (Sieber F, Sieber-Blum M) Cancer Res 1986 Apr;46(4 Pt 2):2072-6 64 Citations |
| 1 | Merocyanine 540-mediated photosensitization of leukemia and solid tumor cells. (Sieber F) Prog Clin Biol Res 1985;172B:227-34 3 Citations |
| 1 | Selective killing of leukemic cells by merocyanine 540-mediated photosensitization. (Sieber F, Spivak JL, Sutcliffe AM) Proc Natl Acad Sci U S A 1984 Dec;81(23):7584-7 143 Citations |
| 1 | Susceptibility to merocyanine 540-mediated photosensitization: a differentiation marker on murine hematopoietic progenitor cells. (Meagher RC, Sieber F, Spivak JL) J Cell Physiol 1983 Jul;116(1):118-24 49 Citations |
| 1 | Susceptibility to merocyanine 540-mediated photosensitization as a differentiation marker in murine hematopoietic stem cells. (Sieber F, Meagher RC, Spivak JL) Prog Clin Biol Res 1982;85 Pt B:135-44 |
| 1 | Differential sensitivity of mouse hematopoietic stem cells to merocyanine 540. (Sieber F, Meagher RC, Spivak JL) Differentiation 1981;19(1):65-7 30 Citations |
© 2023 Clinical & Translational Science Institute